Kromatid Joins California Institute for Regenerative Medicine Resource Program
Kromatid has been named a partner in the California Institute for Regenerative Medicine (CIRM) industry resource program, providing genomic analysis services for cell and gene therapy.
Kromatid, a company specializing in analytical cytogenetics, has been selected as a member of the industry resource partnership program at the California Institute for Regenerative Medicine (CIRM). The move aims to provide cell and gene therapy developers within the CIRM ecosystem with enhanced access to single-cell genomic analysis tools.
The partnership facilitates collaboration between high-growth biotech firms and the institute’s portfolio of research projects. By integrating Kromatid's analysis capabilities, developers can better monitor genomic integrity throughout the drug development pipeline, addressing a critical need for precision in gene-editing applications.
As regulatory scrutiny regarding the stability of modified cells intensifies, partnerships of this nature are becoming increasingly common to bridge the gap between early-stage research and clinical-grade compliance.